| Expression pattern: |
DN |
| Associated gene: |
RBM39, U2AF65, AR-V7 |
| Associated microRNA: |
miR-145 |
| Biological function: |
potentially associated with development of enzalutamide resistance; potentially linked to splicing regulation via RBM39/U2AF65 and AR-V7 regulation |
| Molecular mechanism: |
Predicted circRNA-miRNA binding (miR-145); association with RBM39/U2AF65 splicing-related pathway and AR-V7 regulation (correlative). |
| Biological pathway or process: |
ceRNA regulation (other); other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; RNase R Treatment; Bioinformatics Analysis |
| Clinical significance: |
Potential biomarker relevance is suggested (detectable differences by malignancy status and androgen dependency in cell lines), but no patient outcome/diagnostic performance is reported. |
| Description: |
hsa_circ_0004870 (host gene RBM39) is down-regulated in enzalutamide-resistant LNCaP clones and is also lower in malignant and AR-positive contexts in prostate-related cell lines. The study links its deregulation to drug resistance, potentially through RBM39/U2AF65 splicing-related biology and AR-V7 regulation, and predicts miR-145 binding. |
| Confidence score: |
0.3858 |